Imidazolidinedione derivatives

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

546 15, 548309, 424256, 424273R, A61K 31435, C07D40114

Patent

active

044643802

ABSTRACT:
A series of novel spiro-oxindole imidazolidinedione derivatives have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as aldose reductose inhibitors for the control of certain chronic diabetic complications. Preferred compounds include 6'-amino-spiro-[imidazolidine-4,3'-indoline]-2,2',5-trione, 5'-chloro-7'-amino-spiro-[imidazolidine-4,3'-indoline]-2,2',5-trione, 1'-(3-pyridylmethyl)-5'-fluoro-spiro-[imidazolidine-4,3'-indoline]-2,2',5- trione, 1'-(3-pyridylmethyl)-5',7'-dichloro-spiro-[imidazolidine-4,3'-indoline]-2, 2',5-trione and spiro-[imidazolidine-4,3'-(6-azaindoline)]-2,2',5-trione. Methods for preparing these compounds from known starting materials are provided.

REFERENCES:
patent: 3821383 (1974-06-01), Sestanj et al.
patent: 4200642 (1980-04-01), Schnur
H. Otomasu et al., "Spiro Heterocyclic Compounds. I. Synthesis of Spiro-[imidazoline-4,3'-indoline]-2,2',5-triones", Chem. Pharm., Bull., (Tokyo), vol. 23, No. 7, p. 1431, (1975).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Imidazolidinedione derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Imidazolidinedione derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazolidinedione derivatives will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-603601

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.